• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual "Faces of Glaucoma" Campaign and Fundraising Challenge

    1/7/25 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit organization dedicated to curing glaucoma, are launching the second annual "Faces of Glaucoma" campaign. The campaign, which will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide,1 will take place throughout Glaucoma Awareness Month in January.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107193963/en/

    "It's estimated that half of people with glaucoma don't know that they have it, demonstrating a need for continuing education and awareness efforts," said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb. "In collaboration with Glaucoma Research Foundation, we aim to encourage people to take an active role in understanding and managing their risk, starting with seeing an eye doctor."

    Throughout January, Bausch + Lomb and GRF will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease and encourage proactive eye health management. In addition, for the fourth consecutive year, Bausch + Lomb will support a fundraising challenge in which every dollar raised will be matched up to $20,000. These funds will support GRF research into a potential glaucoma cure.

    Glaucoma symptoms can develop gradually and may go unnoticed. Although there is currently no cure for glaucoma, early intervention – including prescription eye drops – can help slow the disease's progression. Only an eye care professional can diagnose glaucoma, typically through a yearly comprehensive dilated eye exam.1,2

    "While glaucoma is often thought of as an older person's disease, it's important to understand that it can impact anyone, regardless of race, age or gender. This year we build on our previous efforts by highlighting a new group of diverse patient stories to bring to life the many faces of glaucoma," said Thomas M. Brunner, president & CEO, Glaucoma Research Foundation. "We are grateful for the ongoing partnership with Bausch + Lomb and excited to be working with them again."

    To learn more about the fundraising challenge and listen to patient stories, visit https://glaucoma.org/faces-of-glaucoma/.

    About Glaucoma

    Glaucoma is a chronic, progressive disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve. The optic nerve is responsible for the communication of information between the eye and brain. Damage to the optic nerve can lead to severe vision loss, and in the worst case, blindness. As one of the leading causes of preventable blindness, glaucoma affects about four million people in the United States, but if caught early, it is possible to help slow and potentially prevent vision loss.2-4

    About Bausch + Lomb

    Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

    About Glaucoma Research Foundation

    Founded in San Francisco in 1978, Glaucoma Research Foundation (GRF) is America's oldest and most experienced institution dedicated solely to its mission: to cure glaucoma and restore vision through innovative research. GRF has a proven track record of ground-breaking, results-oriented research and produces definitive educational materials used by eye care professionals across the country. The Glaucoma Research Foundation website, www.glaucoma.org, provides valuable information about glaucoma to millions of visitors annually.

    References

    1. U.S. Centers for Disease Control and Prevention. About Glaucoma. Retrieved from https://www.cdc.gov/vision-health/about-eye-disorders/glaucoma.html. Reviewed on Nov. 12, 2024.
    2. National Eye Institute. Glaucoma and Eye Pressure. Retrieved from https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma/glaucoma-and-eye-pressure. Reviewed on Nov. 12, 2024.
    3. John Hopkins. Glaucoma. Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma. Reviewed on Nov. 12, 2024.
    4. Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmol. 2024;142(11):1046–1053. doi:10.1001/jamaophthalmol.2024.3884

    © 2024 Bausch + Lomb.

    BLNP.0231.USA.24

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250107193963/en/

    Bausch + Lomb Media Contact:

    Caryn Marshall

    [email protected]

    (908) 493-1381

    Glaucoma Research Foundation Media Contact:

    Andrew J. Jackson

    [email protected]

    (415) 986-3162

    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

    Bausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research Bausch + Lomb will also sponsor The Glaucoma Foundation's annual month-long educational social media campaign, which spotlights stories from glaucoma patients and advocates Glaucoma affects about four million people in the United States1 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in Ja

    1/5/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the "Fourth Amendment") to its existing credit agreement providing for a $2,802,125,000 tranche (the "Replacement Term Loans") of new term B loans, the proceeds of which were used to refinance all of its outstanding term B loans due 2031 (the "Third Amendment Term Loans") and its outstanding term B loans due 2028 (the "First Incremental Term Loans"). The am

    1/2/26 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    1/2/26 4:10:34 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Amendment: Bausch + Lomb Corporation filed SEC Form 8-K: Leadership Update

    8-K/A - Bausch & Lomb Corp (0001860742) (Filer)

    12/22/25 4:10:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by Bausch + Lomb Corporation

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    12/17/25 4:44:26 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Collis Steven H

    3 - Bausch & Lomb Corp (0001860742) (Issuer)

    1/9/26 6:39:51 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Alfonso Eduardo

    3 - Bausch & Lomb Corp (0001860742) (Issuer)

    1/9/26 6:06:45 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Robertson Russel C was granted 1,642 shares, increasing direct ownership by 3% to 66,556 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    11/18/25 4:42:57 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/27/25 8:16:24 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/6/25 4:30:10 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    8/7/24 5:29:48 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Third-Quarter 2025 Results

    Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con

    10/29/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T

    9/29/25 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations